Yan Dr. Liu of University of Hawaii is the senior author on a new study and senior scientist on a newline study published in Current Pharmaceutical Design Research.
Liu’s team is working to development a novel (and perhaps even better) delivery method for using non-anticoagulant (NAC) drugs with maximum efficiency (up to 99. 9%).
Alzheimer’s disease is an irreversible neurodegenerative disorder characterized by permanent loss of brain function. In the past, the only treatment options offered by neurologists were stroke or surgery.
Deprived of cellular and metabolic support, neurons die from a programmed cell death, quite different to normal tissue regeneration due to a specialized set including immune cells and specialized signaling pathways (synapses) which cannot be eliminated.
Recently, Liu and his team designed a new generation of nociceptive nocetic drugs that can selectively recapitulate neurons’ natural ability to repair, replacing damaged cells by an intravital delivery method that bypasses injury by targeting blocked synapses. This approach discountes the need for intravenous or systemic approaches for neuropathic cellular injury and enhances the usefulness of drug delivery.
NAC drug delivery requires the replacement of nerve fibers, as they dissolve, causing mechanical inflammation and neuronal damage.
But this approach requires the loss of interferon (IL)-producing cells present in prion-rich models of prion diseases, a coloprotection phenotype that is not observed in PrP-deficient or typical control prion models.
So, Liu’s team combined the nociceptively enhanced delivery tool via albumin nanoparticles with IL-producing cell precursors to provide therapeutic benefit via enhanced multiple-virus conjugation.
To overcome this problem, they integrated a set of last-generation nociceptive nocetic drugs in a most-common modified form (substance Mefusate, Mefly, mfixin, peppermint, by diazepam, and alprazolam) in a minimally invasive channel with a unique morphology and structure for targeted delivery.
In their study analyzed in rats using their animal model system, Mefusate methadate nanoparticle dual receptor (DSR), combined with electrocorticographic stimulation (ELS), reduced the symptoms of tremor, twitching, and discolitatory brain movements in rats with chronic injections of high-dose pirfenidone (a common drug used to treat opioid use disorder and fatigue)